Please assess the completion status of the following clinical trial:

Trial Title: Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)~* Must have evidence of brain metastases by MRI or CT scan~PRIOR CONCURRENT THERAPY:~* Recovered from prior oncologic or major surgery~* Prior resection of all brain metastases or only site of brain metastases allowed provided there is radiologically evaluable intracranial metastases~* No prior cranial irradiation, including stereotactic radiosurgery~* More than 30 days since prior non-approved or investigational drug~* No other concurrent chemotherapy, immunotherapy, hormonal therapy, radiotherapy, surgery, or experimental medications~  * No single brain metastases or oligometastatic disease amenable to surgical resection or radiosurgery~* Relapsed NSCLC with brain metastases allowed~* Not a candidate for double-agent or platinum-based chemotherapy~* No leptomeningeal metastases~* No clinically relevant (defined by physical exam) pleural effusions or ascites that cannot be controlled with drainage or other procedures~Inclusion Criteria:~* Karnofsky performance status 70-100% OR ≥ 70 years of age~* Life expectancy \> 3 months~* Absolute neutrophil count (ANC) \> 1,500/mm³~* Platelet count \> 100,000/mm³~* Hemoglobin ≥ 8 g/dL~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* Creatinine clearance ≥ 45 mL/min~* Able to take vitamins, folic acid, and corticosteroids~Exclusion Criteria:~* Contraindication or intolerance to corticosteroid therapy~* Other malignancies within the past 5 years and disease-free OR prognosis is best defined by the NSCLC in the opinion of the attending physician~* Pregnant or nursing~* Positive pregnancy test~* Fertile patients must use effective contraception~* HIV positive~* Severe hypersensitivity to pemetrexed disodium~* Unable to discontinue NSAIDs for ≥ 5 days~* History of underlying dementia, Parkinson's disease, or Alzheimer's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm Study (Type: OTHER): Single Arm Study

Based on this trial design, predict the completion outcome and termination type (if applicable).